Together, these results suggest that intranasal S100A8 treatment contributes to the reprogramming of the lung microenvironment to reduce ROS and NO and creates a potentially more favorable microenvironment for supporting anti-cancer lymphocytes. This evidence concerns the gene S100A8 and cancer.